Abstract
Background
Lung cancer is the leading cause of cancer-related deaths in the world. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. For lack of conveniently sensitive and specific biomarkers, the majority of patients are in the late stage at initial diagnosis. Long non-coding RNAs (LncRNAs), a novel type of non-coding RNA, have recently been recognized as critical factors in tumor initiation and progression, but the role of exosomal LncRNAs has not been thoroughly excavated in NSCLC yet.
Methods
We isolated exosomes from the serum of patients with NSCLC and healthy controls. Exosome RNA deep sequencing was subsequently performed to detect differentially expressed exosomal LncRNAs. qRT-PCR assay was then utilized to validate dysregulated LncRNAs in both testing and multicentric validation cohort. Receiver operating characteristic (ROC) curve was used to detect the diagnostic capability of exosomal biomarkers. Furthermore, Kaplan–Meier analysis was applied to evaluate the prognostic values of these molecules.
Results
On the basis of analysis, we found that novel exosomal LncRNA RP5-977B1 exhibited higher levels in NSCLC than that in the healthy controls. The area under the curve (AUC) value of exosomal RP5-977B1 was 0.8899 and superior to conventional biomarkers CEA and CYFRA21-1 both in testing and multicentric validation cohort. Interestingly, the diagnostic capability of exosomal RP5-977B1 was also validated in early-stage patients with NSCLC. Furthermore, high expression of exosomal RP5-977B1was closely related with worse prognosis in NSCLC (P = 0.036).
Conclusions
Our results suggested that exosomal RP5-977B1 might serve as a novel “liquid biopsy” diagnostic and prognostic biomarker to monitor NSCLC and improve possible therapy.
Similar content being viewed by others
Avoid common mistakes on your manuscript.
Introduction
Lung cancer (LC) is a leading cause of cancer-related mortality worldwide. Among all lung cancer cases, more than 80% are non-small cell lung cancer (NSCLC), which can be further subtyped into lung adenocarcinoma (LAD), lung squamous cell carcinoma (LSCC), large cell carcinoma (LCC), and other relatively less frequently diagnosed histological types[1, 2]. Being diagnosed at an advanced stage with a high recurrence rate, the overall 5-year survival rate is below 15%, and the prognosis for the majority of patients is far from satisfactory [3]. Thus, it is urgent to develop novel and effective markers for early diagnosis and prognosis prediction.
Exosomes are secreted membranous vesicles with a size of 30–150 nm [4, 5]. With inward budding of late endosomes, exosomes evolve into internal multivesicular endosomes (MVEs) [4, 6]. In this process, bioactive factors such as DNAs, RNAs, and proteins are encapsulated into exosomes[7]. Notably, RNAs are reported to be the main components of tumor cell-derived exosomes, which can reflect tumor progression and dynamic process of tumor cells [5, 8]. Furthermore, when released into the extracellular environment and enter the peripheral blood system, exosomal RNAs are protected from degradation by endogenous RNases and, thus, increased the stability in the blood stream [9]. Therefore, circulating exosomal RNAs are emerging as the promising biomarkers for early monitoring of cancer and prognostic evaluation of patients.
Long non-coding RNAs (LncRNAs) are a heterogeneous class of transcripts longer than 200 nucleotides in size without coding potential [10,11,12,13,14]. It is found that LncRNAs are abundant in whole blood and involved in carcinogenesis and development of many malignant tumors, including NSCLC [15,16,17]. In the present study, we focused on exosomal LncRNAs to explore its value for early diagnosis and prognostic assessment in NSCLC.
Materials and methods
Patients and clinical samples
As a testing cohort, a total of 178 cases of NSCLC and the healthy serum samples between January 2016 and August 2019 are enrolled from Cancer Center of Guangzhou Medical University (CCGMU). 156 cases of validation cohort was comprised of patients with early-stage NSCLC and recruited from Sun Yat-Sen University Cancer Center, Nanfang Hospital, Southern Medical University and the First Affiliated Hospital of Guangzhou Medical University between April 2017 and January 2020. Benign lung diseases including pulmonary tuberculosis was recruited from Guangzhou Chest Hospital between August and October 2019.
Patients who accepted chemotherapy or radiotherapy before collection were excluded. For the use of these clinical materials for research purposes, prior patient consents and approval from the Institutional Research Ethics Committee of Southern Medical University were obtained. The research was carried out according to the principles set out in the Declaration of Helsinki 1964 and all subsequent revisions, informed consent was obtained, and the relevant institutional review board had approved the study. Clinical information of the samples is described in detail in Table 5.
Exosomal RNA sequencing
Exosomal RNA sequencing was detected by RiboBio biotech company (Guangzhou, China). In briefly, Exosomal RNA was retrotranscribed and amplified to double stranded cDNA and followed by adaptor ligation and enrichment as according to standard protocol of NEBNext® Ultra™ Directional RNA Library Prep Kit. The library products were validated by Agilent 2200 Tape Station (Agilent Technologies) and a Qubit® 2.0 Fluorometer (Life Technologies) and then diluted on a HiSeq3000 paired-end flow cell followed by sequencing (HiSeq3000 system, 2 × 150 bp).
Exosomes isolation and characterization
Exosomes were isolated from human serum as previously described [18]. Briefly, 5 ml of serum was thawed on ice, diluted in 1 × phosphate-buffered saline (PBS) (1:10), and pre-cleared using a 0.22 μm pore filter. Then, the samples were ultracentrifuged at 150,000g overnight at 4 °C. The supernatant solution was discarded, the remaining pellet was washed in 11 ml 1 × PBS followed by ultracentrifugation at 150,000g at 4 °C for 2 h. The exosomes pellet was resuspended in Trizol for RNA isolation, in lysis buffer for WB, or in PBS for transmission electron microscopy (JEM-1200EX, Japan) and Flow NanoAnalyzer (NanoFCM Inc, China). For qRT-PCR assay, exosomes were isolated and purified according to the manufacturer’s instructions using exoEasy Maxi Kit (Qiagen, Germany).
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) was assessed as previously described using the Flow NanoAnalyzer (NanoFCM Inc). After the ultracentrifuge, all the samples were monitored with the use of same injection pressure (1.5 kPa) for 60 s. The samples were diluted at appropriate multiples results in approximately 1000–6000 particles per minute. The process was repeated three times. NTA software was used to measure the size and the concentration of nanoparticles.
Western blotting analysis
Western blotting analysis was performed according to a previously described standard method using the antibodies anti-CD63 (1:1000, Abcam, MA) and anti-CD 9 (1:1000, Abcam) [19]. The blotted membranes were stripped and re-blotted with anti-α-tubulin (1:3000, Abcam) as a loading control.
RNA extraction from exosomes
Total exosomal RNA was isolated using HiPure Exosome RNA Kit (Qiagen) following the standard protocol provided by the manufacturer. RNA purity and concentration was quantified using a Nanodrop® ND-1000 (Thermo Fischer Scientific, MA).
Total RNA isolation
Total RNA was extracted by TRIzol LS Reagent (Invitrogen, Carlsbad, CA) as previously described [19]. Briefly, 500 μl of serum was mixed with an equal volume of TRIzol LS Reagent, incubated for 5 min on ice. Subsequently, 1000 μl of Acid-Phenol: Chloroform (Invitrogen) was added, vortexed and centrifuged for 25 min at 20,000g. The aqueous (upper) phase was collected, and 1.25 volumes of 100% ethanol were added. The RNA was then purified with miRNeasy Mini Kit (Qiagen) in accordance with the manufacturer’s instructions. The RNA concentration was assessed using a NanoDrop ND-1000 instrument (Thermo Fisher Scientific).
Quantitative real-time-PCR (qRT-PCR)
First-strand cDNA was generated from 500 ng of serum circulating RNA using MMLV transcriptase (Promega, WI). qRT-PCR was performed on a CFX96 qRT-PCR detection system (Bio-Rad, Richmond, CA). The expression levels were measured using the \(2^{ - \Delta \Delta C_{{\text{t}}}}\) (\(C_{{\text{t}}}\) is threshold cycle) formula. The sequences of the primers are listed below:
-
RP5-977B1: 5′-TTTGAGGATGCGGGTGAA-3′ (forward)
-
5′-ATGAGGAAGTGGACGAGATG-3′ (reverse)
-
GAPDH: 5′-GACTCATGACCACAGTCCATGC-3′ (forward)
-
5′-AGAGGCAGGGATGATGTTCTG-3′ (reverse)
CEA and CYFRA21-1 detection
The serum CEA and CYFRA21-1 levels were tested using an Elecsys-electrochemical immune assay (Roche, USA) and were detected in a cobas 8000 modular analyzer (Roche).
Statistical analysis
All statistical analyses were carried out using the SPSS 20.0 statistical software package. Survival curves were analyzed by the Kaplan–Meier method, and a log-rank test was used to assess significance. Patients were classified into high-expression or low-expression group by using the corresponding median value as the cutoff point (fold change > 1.5). The correlation between the expression levels of RP5-977B1 and clinical parameters of patients was assayed by a Chi-square test. Receiver operating characteristic curves (ROC) was used to determine diagnostic metrics that were calculated using Delong method [20]. Student’s t test was used to compare between groups. In all cases, error bars represent the mean ± SD derived from three independent experiments. P values < 0.05 were considered statistically significant.
Results
RNA sequencing-based screening of dysregulated exosomal LncRNAs in NSCLC
To identify the dysregulated exosomal LncRNAs in NSCLC, we collected serum specimens from patients diagnosed with NSCLC (n = 3) and healthy controls (n = 3). After isolation of serum exosomes by differential ultracentrifugation, transmission electron microscopy (TEM) and NanoSight particle tracking were applied for identification and quantification of exosomes. As shown in Fig. 1A, exosomes obtained from NSCLC patients and healthy people exhibited similar typical lipid bilayer membrane morphology. Specific protein positive markers (CD9 and CD63) and negative control (α-tubulin) were used to identify the exosomes [18] (Fig. 1B). Furthermore, we found that the particle size distribution of exosomes was mainly around 30–150 nm and concentrations was enough to analyze (Supplementary Fig. 1).
Next, exosomal RNA was extracted, purified, and further analyzed via RNA sequencing (Fig. 1C and Supplementary Table 1). According to expression profiles, up-regulated exosomal LncRNAs were detected and verified at first in NSCLC.
Verification the expression levels in the testing cohort
To further validate the sequencing data, we performed qRT-PCR assay to detect significantly overexpressed LncRNAs. As shown in Fig. 2A, exosomal RP5-977B1 was significantly overexpressed in NSCLC, while other assessed LncRNAs showed no significant or only weak effects, suggesting that RP5-977B1 might be the candidate molecule for further study (Fig. 2A). Pulmonary tuberculosis was the common benign pulmonary lesions that increased the difficulty of detecting NSCLC with existing detection method, so we included it in the control group. Further analysis was focused on the expression of RP5-977B1 in the testing sets with 178 serum specimens, qRT-PCR assays indicated that exosomal RP5-977B1 was significantly up-regulated in patients with NSCLC and early-stage NSCLC, when compared with healthy and pulmonary tuberculosis controls (Fig. 2B, C). We next examined the expression of conventional markers Carcinoembryonic Antigen (CEA) and Cytokeratin 19 Fragment (CYFRA21-1) in the testing sets. As shown in Fig. 2D–G, CEA and CYFRA21-1 levels were also increased in patients with NSCLC when compared with healthy controls, while significant difference was discovered between healthy and pulmonary tuberculosis controls as well (Fig. 2D–G).
Diagnostic power of exosomal RP5-977B1 in the testing cohort
Furthermore, the receiver operating characteristic (ROC) curve (AUC) was drawn to assess the diagnostic value of exosomal RP5-977B1. Exosomal RP5-977B1 revealed an AUC value of 0.8899 (P < 0.001) in distinguishing patients with NSCLC from the healthy and patients with pulmonary tuberculosis, while serum CEA and CYFRA21-1 shown an AUC = 0.7609 (P < 0.001) and 0.6703 (P = 0.0001), respectively (Fig. 3A, Table 1). The AUC value of RP5-977B1 was significantly higher than CEA and CYFRA21-1 (P < 0.05, Table 2). For early-stage NSCLC (stage I and II), exosomal RP5-977B1 was superior in distinguishing patients from controls (for stage I and II patients, AUC = 0.8658, P < 0.001), while serum CEA and CYFRA21-1 revealed an AUC = 0.7011 (P = 0.0003) and 0.5792 (P = 0.5792), respectively (Fig. 3B, Tables 1, 2). Diagnostic advantage was also achieved for stage I patients (for exosomal RP5-977B1, AUC = 0.8377, P < 0.001, for serum CEA, AUC = 0.5694, P = 0.3920, for serum CYFRA21-1, AUC = 0.5792, P = 0.1521), indicating that exosomal RP5-977B1 exhibited advantages in the diagnosis of early-stage NSCLC (Fig. 3C, Tables 1, 2).
Detection of exosomal RP5-977B1 in the validation cohort
We further detected the expression of exosomal RP5-977B1 in a multicentric early-stage cohort with 156 serum specimens (67 NSCLC patients with early stage and 89 healthy and tuberculosis controls). As shown in Fig. 4A–C, exosomal RP5-977B1 was highly expressed in NSCLC patients with stage I and II, while not in control patients with pulmonary tuberculosis (Fig. 4A). Serum CEA and CYFRA21-1 also showed elevated levels in early-stage NSCLC, but failed to distinguish patients with pulmonary tuberculosis from NSCLC (Fig. 4B, C). Corresponding to these results, the AUCs of RP5-977B1, CEA and CYFRA21-1 in the validation cohort were 0.8686 (P < 0.001), 0.6878 (P < 0.001) and 0.6361 (P = 0.0037) in distinguishing early-stage NSCLC from controls (Fig. 4D). Furthermore, the AUCs of RP5-977B1, CEA and CYFRA21-1 were 0.8638 (P < 0.001), 0.5840 (P = 0.1261) and 0.6670 (P = 0.3174) in distinguishing patients with stage I from controls (Fig. 4E, Table 3). The AUC value of RP5-977B1 was significantly higher than CEA and CYFRA21-1 (P < 0.05, Table 4), diagnostic accuracy of exosomal RP5-977B1 for early-stage NSCLC was also verified in the validation cohort.
Validation the existing pattern of RP5-977B1
We next explored whether RP5-977B1 was mainly existed in exosomes. To this end, 21 cases of NSCLC serum samples were directly incubated with RNase A, or both RNase A and Triton X-100. As shown in Fig. 5A, the levels of RP5-977B1 were constant when treated with RNase A, but decreased significantly upon RNase A and Triton X-100 treatment (Fig. 5A). It was indicated that RP5-977B1 was mainly encapsulated by exosomes rather than released directly. Moreover, the amount of RP5-977B1in serum was predominant in the exosomes, but significantly reduced in exosomes-depleted serum (Fig. 5B). As expected, the levels of RP5-977B1 in serum exosomes were positively correlated with peripheral blood according to the results of correlation coefficient (r2 = 0.8082, P < 0.01) (Fig. 5C). Taken together, these results suggested that exosome was the main existing pattern of RP5-977B1 in the peripheral blood.
Exosomal RP5-977B1 levels indicated worse prognosis of NSCLC patients
The significant increase of exosomal RP5-977B1 in early-stage NSCLC prompted us to investigate whether RP5-977B1 could predict the prognosis in NSCLC. To achieve this end, we collected the clinical information of the patients, which was summarized in Table 5. By analyzing these data, we found that RP5-977B1 level was significantly correlated with tumor stage and distant metastasis, which contributed to the further intensive study (Table 6).
Stratified by a median cutoff of RP5-977B1 expression, we found that higher RP5-977B1 expression indicated shorter overall survival than those lower levels of RP5-977B1 (P = 0.036) (Fig. 6A). Serum CEA and CYFRA21-1 were also reported to indicate the prognosis in the previous study [21, 22]. As shown in Fig. 6B, C, high CEA and CYFRA21-1 levels were related with shorter survival time (Fig. 6B, C). Collectedly, these results indicated that exosomal RP5-977B1 might have the potential to predict the prognosis of NSCLC.
Discussion
Our current study reports a novel exosomal LncRNA, RP5-977B1, which was up-regulated in NSCLC, as evidenced by RNA sequencing and qRT-PCR assay. With encapsulating into exosomes, RP5-977B1 has high stability and easy access to monitor in circulation, which contributed to be the promising candidate molecules for dynamic detection. ROC curves data supported that RP5-977B1 could discriminate patients with early-stage NSCLC from controls with privileging sensitivity and specificity. Furthermore, survival analyses indicated that high level of RP5-977B1 was associated with shorter survival time in NSCLC. Collectedly, our study demonstrated that exosomal LncRNA RP5-977B1 showed the potential to be the biomarker for early diagnosis and prognosis prediction in NSCLC.
With unique properties of stability and dynamic detection, exosomes develop to be the promising carrier for various molecules, in particular LncRNAs [23, 24]. It was reported that exosomes transport a preponderance of LncRNAs, which almost reached 20.19% of exosomal RNAs extraction in the plasma of castration-resistant prostate cancer patients [25]. In this study, we find that LncRNA RP5-977B1 was exported by exosomes and exhibited elevated levels in NSCLC through RNA sequencing. Analyzing the sequencing results, the number of up-regulated LncRNAs was listed limited, the cause may be largely due to the insufficient sequencing depth. More overexpressed LncRNAs are expected to study and excavate further. RP5-977B1 was found to be a highly conservative LncRNA that located on chromosome 20 and contains two exons. Ensembl Genome Browser (version 90; http://www.ensembl.org/index.html) showed that the full length of RP5-977B1 is 714 nt, which was equipped with the basic characteristics of an LncRNA. Of particular note, it is the pioneering study to investigate LncRNA RP5-977B1 and explore its diagnostic and prognostic potential for NSCLC.
Operation is the most effective therapy for early-stage NSCLC with clear surgical indication [26]. Due to initial diagnosis at advanced stage, less than 30 percent of patients accept surgically resectable tumors [27, 28]. Studies analyzing the results of different treatment suggest that mortality rate would be further decreased if diagnosed at early stage. Conventional screening of NSCLC with MRI or CT would be exorbitantly expensive and relevant to high rates of false positives, while tumor markers provide complementary risk assessment for the clinic decision making. Patients with NSCLC show high levels of tumor markers CEA and Cyfra21-1 [29,30,31], while they are not specifically overexpressed at early stage, which facilitates the establishment of new and effective diagnostic or prognostic biomarkers. Exosomal RP5-977B1 was overexpressed in serum of early-stage NSCLC with reliable sensitivity and specificity in distinguishing patients of NSCLC from the healthy and pulmonary tuberculosis, exhibiting satisfactory potential for diagnostic markers.
The heterogeneity of NSCLC results in that even if patients at same stage and accept the same therapy, the prognosis can be the opposite [32, 33]. Accumulating evidence has indicated that specific LncRNA expression was correlated with clinical features in various types of cancers, supporting the utility of LncRNA in prognosis of the disease [34, 35]. Moreover, detection of peripheral blood exosomal LncRNA makes repeated measurements minimally invasive and reveals the survival status for patients over time. In this study, we found that high levels of exosomal RP5-977B1 indicated worse prognosis and was significantly correlated with tumor stage and distant metastasis. Cedrés et al. has reported that CEA and Cyfra21-1 are a prognostic indicator of poor survival in NSCLC [21, 22, 36]. Our study showed that CEA and Cyfra21-1 were also positively related with worse prognosis, while CEA indicated no statistical difference, may be due to the limited sample size. Conclusively, exosomal RP5-977B1 may be the promising candidate serum-based biomarkers for dynamical monitoring the prognosis in NSCLC.
Given the clinical significance of RP5-977B1in NSCLC, we find that exosomal RP5-977B1 can be novel diagnostic and prognostic biomarkers for NSCLC patients. Exosomes are the leading carrier for LncRNA RP5-977B1 cargo, with better stability and reproducible detection, exosomal RP5-977B1 is expected to become non-invasive biomarkers for NSCLC.
Conclusions
To date, biomarker for early diagnosis was not fully explored in NSCLC. With stabilization and considerable tumor specificity, exosomal LncRNA developed to be the ideal tumor diagnostic marker. Our findings suggest exosomal LncRNA RP5-977B1 had favorable sensitivity and specificity for early diagnosis in NSCLC, which supposed to be the novel diagnostic biomarker in the future. Exosomal RP5-977B1 level was also negatively related with prognosis of NSCLC, and correlated with tumor stage and distant metastasis, indicating its potential for serum-based biomarker of prognosis. Our results provide the new sights into early diagnosis and drug therapy targets in NSCLC.
References
“Cancer statistics, 2021” (2021) CA Cancer J Clin 71(4):359. https://doi.org/10.3322/caac.21669
Ferlay J, Soerjomataram I, Dikshit R et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359–E386
Rami-Porta R, Asamura H, Travis WD et al (2017) Lung cancer—major changes in the american joint committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 67:138–155
Raposo G, Stoorvogel W (2013) Extracellular vesicles: exosomes, microvesicles, and friends. J Cell Biol 200:373–383
Tkach M, Thery C (2016) Communication by extracellular vesicles: where we are and where we need to go. Cell 164:1226–1232
van Niel G, Porto-Carreiro I, Simoes S et al (2006) Exosomes: a common pathway for a specialized function. J Biochem 140:13–21
Qian Wang LZ. (2019). Extracellular vesicles: basic research and clinical application: science press
Huang YK, Yu JC (2015) Circulating microRNAs and long non-coding RNAs in gastric cancer diagnosis: an update and review. World J Gastroenterol 21:9863–9886
Liu T, Zhang X, Gao S et al (2016) Exosomal long noncoding RNA CRNDE-h as a novel serum-based biomarker for diagnosis and prognosis of colorectal cancer. Oncotarget 7:85551–85563
Vendramin R, Marine JC, Leucci E et al (2017) Non-coding RNAs: the dark side of nuclear-mitochondrial communication. EMBO J 36:1123–1133
Zhou N, He Z, Tang H et al (2019) LncRNA RMRP/miR-613 axis is associated with poor prognosis and enhances the tumorigenesis of hepatocellular carcinoma by impacting oncogenic phenotypes. Am J Transl Res 11:2801–2815
Mo Y, He L, Lai Z et al (2018) LINC01287/miR-298/STAT3 feedback loop regulates growth and the epithelial-to-mesenchymal transition phenotype in hepatocellular carcinoma cells. J Exp Clin Cancer Res 37:149
Wang F, Yang H, Deng Z et al (2016) HOX Antisense lincRNA HOXA-AS2 promotes tumorigenesis of hepatocellular carcinoma. Cell Physiol Biochem 40:287–296
Huang JL, Zheng L, Hu YW et al (2014) Characteristics of long non-coding RNA and its relation to hepatocellular carcinoma. Carcinogenesis 35:507–514
Conigliaro A, Costa V, Lo DA et al (2015) CD90+ liver cancer cells modulate endothelial cell phenotype through the release of exosomes containing H19 lncRNA. Mol Cancer 14:155
Li Z, Jiang P, Li J et al (2018) Tumor-derived exosomal lnc-Sox2ot promotes EMT and stemness by acting as a ceRNA in pancreatic ductal adenocarcinoma. Oncogene 37:3822–3838
Guo FX, Wu Q, Li P et al (2019) The role of the LncRNA-FA2H-2-MLKL pathway in atherosclerosis by regulation of autophagy flux and inflammation through mTOR-dependent signaling. Cell Death Differ 26:1670–1687
Lin LY, Yang L, Zeng Q et al (2018) Tumor-originated exosomal lncUEGC1 as a circulating biomarker for early-stage gastric cancer. Mol Cancer 17:84
Guan H, Zhu T, Wu S et al (2019) Long noncoding RNA LINC00673-v4 promotes aggressiveness of lung adenocarcinoma via activating WNT/beta-catenin signaling. Proc Natl Acad Sci USA 116:14019–14028
DeLong ER, DeLong DM, Clarke-Pearson DL et al (1988) Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 44:837–845
Lin XF, Wang XD, Sun DQ et al (2012) High serum CEA and CYFRA21-1 levels after a two-cycle adjuvant chemotherapy for NSCLC: possible poor prognostic factors. Cancer Biol Med 9:270–273
Cedres S, Nunez I, Longo M et al (2011) Serum tumor markers CEA, CYFRA21-1, and CA-125 are associated with worse prognosis in advanced non-small-cell lung cancer (NSCLC). Clin Lung Cancer 12:172–179
Melo SA, Sugimoto H, O’Connell JT et al (2014) Cancer exosomes perform cell-independent microRNA biogenesis and promote tumorigenesis. Cancer Cell 26:707–721
Mathieu M, Martin-Jaular L, Lavieu G et al (2019) Specificities of secretion and uptake of exosomes and other extracellular vesicles for cell-to-cell communication. Nat Cell Biol 21:9–17
Huang X, Yuan T, Liang M et al (2015) Exosomal miR-1290 and miR-375 as prognostic markers in castration-resistant prostate cancer. Eur Urol 67:33–41
Glanville AR, Wilson BE (2018) Lung transplantation for non-small cell lung cancer and multifocal bronchioalveolar cell carcinoma. Lancet Oncol 19:e351–e358
Berzenji L, Van Schil PE (2019) Surgery or stereotactic body radiotherapy for early-stage lung cancer: two sides of the same coin? Eur Respir J. https://doi.org/10.1183/13993003.00711-2019
Endo S, Ikeda N, Kondo T et al (2017) Model of lung cancer surgery risk derived from a japanese nationwide web-based database of 78 594 patients during 2014–2015. Eur J Cardiothorac Surg 52:1182–1189
Jiang ZF, Wang M, Xu JL et al (2018) Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci 194:1–6
Grunnet M, Sorensen JB (2012) Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer 76:138–143
Chen W, Zheng R, Baade PD et al (2016) Cancer statistics in China, 2015. CA Cancer J Clin 66:115–132
Dong N, Shi L, Wang DC et al (2017) Role of epigenetics in lung cancer heterogeneity and clinical implication. Semin Cell Dev Biol 64:18–25
Xu M, Wang DC, Wang X et al (2017) Correlation between mucin biology and tumor heterogeneity in lung cancer. Semin Cell Dev Biol 64:73–78
Zhai W, Sun Y, Guo C et al (2017) LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ 24:1502–1517
Zhao L, Ji G, Le X et al (2017) Long noncoding RNA LINC00092 acts in cancer-associated fibroblasts to drive glycolysis and progression of ovarian cancer. Res 77:1369–1382
Sone K, Oguri T, Ito K et al (2017) Predictive role of CYFRA21-1 and CEA for subsequent docetaxel in non-small cell lung cancer patients. Anticancer Res 37:5125–5131
Funding
This work was supported by the Youth Program of National Natural Science Foundation of China (No.81902991); Guangzhou Science and Technology Plan Project (No.202102021056); Guangdong Provincial Science and Technology Program (No.2017A020215103).
Author information
Authors and Affiliations
Contributions
QW and LM conceived the study. QW and LZ supervised the study. QW, TZ, BL and TA devised all analyses. QW and LM wrote the original manuscript. TA and LZ reviewed and edited the manuscript. LM, TZ and BL performed statistical analyses and interpreted data. TA, QZ and YS provided the clinical sample and information. ZY performed western blot assay. All authors have read and agreed to the published version of the manuscript.
Corresponding author
Ethics declarations
Conflict of interest
The authors have declared that no conflict of interest exists.
Ethical approval
The study was conducted according to the guidelines of the Declaration of Helsinki and approved by Ethics Committee of Nanfang Hospital, Southern Medical University (NFEC-2016-010).
Informed consent
Informed consent was obtained from all subjects involved in the study.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Below is the link to the electronic supplementary material.
Rights and permissions
This article is published under an open access license. Please check the 'Copyright Information' section either on this page or in the PDF for details of this license and what re-use is permitted. If your intended use exceeds what is permitted by the license or if you are unable to locate the licence and re-use information, please contact the Rights and Permissions team.
About this article
Cite this article
Min, L., Zhu, T., Lv, B. et al. Exosomal LncRNA RP5-977B1 as a novel minimally invasive biomarker for diagnosis and prognosis in non-small cell lung cancer. Int J Clin Oncol 27, 1013–1024 (2022). https://doi.org/10.1007/s10147-022-02129-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10147-022-02129-5